Clinical Trial Update: Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating adding pembrolizumab to olaparib for metastatic pancreatic cancer with BRCA mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING